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Abstract
Background: The aim of the present study was to investigate whether selenium levels differ between type 2
diabetic subjects with and without coronary artery disease (CAD).
Methods: A total of 200 subjects with type 2 diabetes (100 with CAD and 100 without CAD), consecutively
selected from the diabetes outpatient clinic of our hospital were enrolled into the study. A detailed medical history
and a physical examination were obtained by all the participants.
Results: Serum selenium levels did not differ between diabetic subjects with and without CAD (102.40 ± 31.10 vs.
108.86 ± 33.88 microg/L, p = 0.16). In diabetic subjects with CAD multivariate linear regression analysis
demonstrated significant independent associations between selenium and sex (beta = 0.21, p = 0.03) and glucose
levels (beta = 0.25, p = 0.008). In diabetic subjects without CAD multivariate linear regression analysis
demonstrated significant independent associations between selenium and peripheral artery disease (beta = 0.16,
p = 0.05) and glucose levels (beta = -0.09, p = 0.05).
Conclusion: Serum selenium levels did not differ between diabetic subjects with and without CAD. In diabetic
subjects with CAD, the only determinants of serum selenium levels were sex and glucose levels. In diabetic
subjects without CAD the only determinants of serum selenium levels were peripheral artery disease and glucose
levels.
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Background
Studies have showed that selenium is an essential trace
element mainly involved in the complex system of
defense against oxidative stress [1,2], thyroid function
and immune functions [3]. Despite the above functions,
studies have showed a potential association between
serum selemium levels and cardiovascular risk [4-7].
High selenium levels have been associated with higher
prevalence of hypertension [7]. However, the existing lit-
erature data are still inconsistent [4-7]. Despite the
reports showing association between low serum sele-
nium levels and increased cardiovascular mortality and
morbidity, the protective role of selenium against cardi-
ovascular diseases still remains debated [3].
T h ee x i s t i n gl i t e r a t u r ed a t ar egarding the relationship
between serum selenium levels and type 2 diabetes
(T2D) are controversial [8-13]. Some studies showed
lower serum selenium levels in diabetic subjects com-
pared with nondiabetic subjects [8,9]. Experimental data
showed that selenium might play a role to the regulation
of specific beta-cell target genes and potentially pro-
motes an overall improvement in islet function [10]. On
the other hand, it has been showed that high serum
selenium levels were positively associated with the pre-
valence of diabetes [11]. In addition, serum selenium
levels have been associated with the onset of T2D. It
was hypothesized that high levels of selenium might pre-
vent diabetes [12]. However, recent studies found that
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may increase the risk for the disease [13,14].
Since the existing literature data regarding the role of
serum selenium levels to diabetes and its complications
are controversial we conducted the present study in
order to investigate whether selenium levels differ
between T2D subjects with and without coronary artery
disease (CAD).
Methods
Subjects and procedures
A total of 100 type 2 diabetic subjects with CAD and
100 diabetic subjects without CAD, consecutively
selected from the diabetes outpatient clinic of our hos-
pital were enrolled into the study from December 2009
to May 2010. Diagnosis of diabetes was based on the
American Diabetes Associati o nc r i t e r i a[ 1 5 ] .T h e yw e r e
questioned about previous and current diseases, use of
medications and their smoking habits, vitamin use, and
a thorough physical examination was performed. Sub-
jects were considered as non-smokers if they have
never smoked or if they had given up smoking for at
least three consecutive years. Subjects that had
received selenium supplements were excluded by the
study. Diet was assessed using a semi-quantitative
food-frequency questionnaire designed to capture diet-
ary habits [16]. The nutritional database maintained by
the Italian National Institute of Nutrition was used to
report the average selenium content of several food-
stuffs [17].
All measurements were performed in the morning,
after 10-12 hours fast. The subjects were advised not to
eat, smoke, or drink coffee before examination. Blood
samples were drawn for measurement of plasma glu-
cose, HbA1c, creatinine, and lipid profile. The antidia-
betic medications were given to the patients at the end
of the examination. Blood pressure was measured three
consecutive times, one minute in apart, in the sitting
position using an appropriate cuff size. The mean values
of the last 2 measurements was calculated and used in
the analysis. Arterial hypertension was defined according
to the current guidelines [18], when systolic was ≥ 140
mmHg or and/or diastolic blood pressure was ≥ 90
mmHg or when the patients were on antihypertensive
treatment. CAD was defined as presence of angina, his-
tory of previous myocardial infarction, positive stress
testing, revascularization procedures or stenosis > 50%
at the coronary arteries. Direct fundoscopy was per-
formed in all subjects through dilated pupils.
Body weight with subjects in light clothing without
shoes and height was measured and body mass index
(BMI) was calculated. Waist circumference was mea-
sured with a soft tape on standing, midway between the
lowest rib and the iliac crest.
The purpose of the study was clearly explained to all
subjects, who then volunteered to participate. The ethics
committee of the General Hospital of Nikaia approved
the study and informed written consent was obtained.
Analytical methods
Fasting serum glucose, lipids and creatinine concentra-
tions were measured on a Technicon analyzer RA-XT.
Low density lipoprotein (LDL) cholesterol concentra-
tions were calculated using the Friedewald formula [19].
HbA1c was measured by high-performance liquid chro-
matography (HPLC) (Roche Diagnostics, Mannheim,
Germany) with a non-diabetic reference range of 4.0-
6.0%. Microalbuminuria was assessed by measuring the
albumin-to-creatinine ratio (ACR) in a random urine
sample on a DCA 2000 analyzer using the immunone-
phelometry technique (Bayer HealthCare LLC, Elkhart,
USA). Appropriate trace-element tubes (Becton-Dickin-
son, Vacutainer; NJ, USA) were used for drawing blood
samples for determination of selenium levels in blood.
Serum levels of selenium were determined by use of
atomic mass spectrometry (ZEEnit 700; Analytical Jena,
Germany).
Statistical analysis
Statistical analysis was preformed using programs avail-
able in the SPSS statistical package (SPSS 10.0, Chicago,
USA). All variables were tested for normal distribution
of the data. Data are shown as mean ± SD, unless it is
stated otherwise. A two sample t-test was used to assess
differences in continuous variables, while a chi-square
test was used for categorical variables. Univariate linear
regression analysis was performed to look for the rela-
tionship between serum selenium and the variables of
interest in the sample population. Then, multivariate
linear regression analyses were performed (backward
stepwise method) to look for independent associations
between serum selenium and the variables of interest.
All independent variables in the multivariate analyses
models were tested for multicolinearity. p < 0.05 (two-
tailed) was considered statistically significant.
Results
Serum selenium levels did not differ between diabetic
subjects with and without CAD (102.40 ± 31.10 vs.
108.86 ± 33.88 microg/L, p = 0.16).
The demographic and clinical characteristics of the
two study groups are showed in Table 1. Of the diabetic
subjects with CAD 30.8% was on treatment with sulpho-
nylurea, 59.8% on metformin, 3.7% on glitazones, 3.7%
on acarbose, 2.8% on megltitinides, 8.4% on DPP-4 inhi-
bitors, and 51.5% on insulin. Of the diabetic subjects
without CAD 47.0% was on treatment with sulphony-
lurea, 69.7% on metformin, 13.6% on glitazones, 3.0% on
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tors, and 44.6% on insulin. Statin use did not differ
between the two study groups (Table 1). Diabetic sub-
jects without CAD had higher values of systolic and dia-
stolic blood pressure compared to diabetic subjects with
CAD. Diabetic subjects with CAD had more often reti-
nopathy and lower serum levels of total and LDL-cho-
lesterol than diabetics without CAD. Diabetic subjects
without CAD used more often vitamins of the B and C
complex than those with CAD. In addition, diabetic
subjects with CAD were more often smokers than dia-
betic subjects without CAD (Table 1).
In diabetic subjects with CAD univariate linear regres-
sion analysis showed that selenium levels were asso-
ciated significantly with gender [standardized regression
coefficient (beta) = 0.25, p = 0.009], BMI (beta = -0.22,
p = 0.02), glucose levels (beta = 0.21, p = 0.03), number
of platelets (beta = -0.19, p = 0.05) and C-reactive pro-
tein (beta = -0.19, p = 0.04). Multivariate linear regres-
sion analysis demonstrated, after controlling for the
Table 1 Demographic and clinical characteristics of diabetic subjects according to the presence (CAD+) or not (CAD-)
of coronary artery disease
CAD (-) CAD (+) P
Males/females (%) 52/48 52/48 -
Age (years) 66.68 ± 9.52 65.60 ± 8.16 0.38
Body mass index (kg/m2) 32.66 ± 5.20 33.20 ± 5.53 0.48
Waist (cm) 104.31 ± 12.51 106.62 ± 12.10 0.18
Systolic blood pressure (mm Hg) 148.65 ± 19.34 142.75 ± 18.24 0.02
Diastolic blood pressure (mm Hg) 80.74 ± 9.68 77.70 ± 9.27 0.02
Duration of diabetes (years) 11.83 ± 8.28 13.23 ± 8.27 -
Smoking (yes) (%) 22 (21.8) 35 (35.7) 0.03
Alcohol consumption (yes) (%) 39 (38.6) 35 (35.7) 0.67
Vitamins (yes) (%) 15 (15.0) 5 (5.1) 0.02
Hypertension (yes) (%) 87 (86.1) 92 (93.4) 0.07
Dyslipidemia (yes) (%) 90 (89.1) 92 (93.4) 0.22
Any retinopathy (yes) (%) 15 (14.9) 27 (27.6) 0.03
Neuropathy (yes) (%) 6 (5.9) 9 (9.2) 0.67
Microalbuminuria (yes) (%) 49 (52.7) 58 (61.1) 0.24
Peripheral artery disease (yes) (%) 7 (5.9) 14 (14.3) 0.09
Treatment for diabetes - - -
Antidiabetic tablets (yes) (%) 81 (80.2) 66 (67.3) 0.04
Insulin (yes) (%) 45 (44.6) 50 (51.5) 0.32
HbA1c (%) 7.58 ± 1.72 7.74 ± 1.74 0.51
Statins (yes) (%) 89 (67.4) 95 (88.8) 0.15
Glucose (mg/dl) 159.83 ± 53.63 160.74 ± 58.53 0.90
Total cholesterol (mg/dl) 181.56 ± 40.80 168.48 ± 43.85 0.03
HDL cholesterol (mg/dl) 46.52 ± 10.99 43.40 ± 10.38 0.04
LDL cholesterol (mg/dl) 106.13 ± 37.92 94.26 ± 37.25 0.03
Triglycerides (mg/dl) 153.14 ± 82.00 158.08 ± 87.97 0.68
Urea (mg/dl) 44.91 ± 23.34 45.77 ± 21.00 0.78
Creatinine (mg/dl) 1.00 ± 0.55 0.99 ± 0.24 0.88
Uric acid (mg/dl) 5.54 ± 1.61 5.65 ± 1.68 0.64
CRP (mg/dl) 4.32 ± 1.16 3.7 ± 1.8 0.52
Ht (%) 40.16 ± 3.66 40.41 ± 3.55 0.11
WBCs (n) 7,561.68 ± 2,038.28 8,040.91 ± 2,196.38 0.11
PLTs (n) 250,980.20 ± 72,600.54 242,969.07 ± 17,043.47 0.66
Serum Selenium (microg/L) 108.86 ± 33.88 102.40 ± 31.10 0.16
Dietary Selenium (microg/L) 1.04 ± 0.47 1.15 ± 0.65 0.19
P values for the comparison between groups with and without metabolic syndrome (MS) by independent samples t-test for continuous variables or by Pearson
c
2 for nominal variables.
HbA1c: glycated hemoglobin A1c; HDL: high density lipoprotein; LDL: low density lipoprotein; CRP: high sensitivity C-reactive protein; Ht: Hematocrit; WBCs: white
blood cells count; PLTs: platelets.
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between selenium and gender (beta = 0.21, p = 0.03)
and glucose levels (beta = 0.25, p = 0.008).
In diabetic subjects without CAD univariate linear
regression analysis showed that selenium levels were
associated significantly with systolic blood pressure (beta
= 0.22, p = 0.01), peripheral artery disease (beta = 0.15,
p = 0.05) and glucose levels (beta = -0.16, p = 0.05).
Multivariate linear regression analysis demonstrated sig-
nificant independent associations between selenium and
peripheral artery disease (beta = 0.16, p = 0.05) and glu-
cose levels (beta = -0.09, p = 0.05) (Table 2).
Discussion
The results of the present study showed that serum sele-
nium levels did not differ between diabetic subjects with
and without CAD. In diabetic subjects with CAD, the
only determinants of serum selenium levels were sex
and glucose levels. In diabetic subjects without CAD the
only determinants of serum selenium levels were periph-
eral artery disease and glucose levels.
The existing literature data regarding serum selenium
levels in diabetic and nondiabetic subjects are conflicting
[20-24]. In a recent study in Asia there were no impor-
tant differences for serum selenium levels in T2D sub-
jects and nondiabetic individuals [12]. On the contrary,
two studies showed that the mean serum selenium levels
in diabetic subjects were significantly lower than in con-
trols [9,21]. In addition, a negative correlation between
the plasma contents of selenium and HbA1c was found,
confirming our findings regarding the relationship
between selenium and glucose levels in both study
groups [20]. Other authors found a statistically signifi-
cant increase in selenium levels in subjects with diabetes
to the control group [10,22]. A cross-sectional analysis
of 8,876 adults over 20 years of age who participated in
the Third National Health and Nutrition Examination
Survey in the USA showed that high serum selenium
levels were positively associated with the prevalence of
diabetes [11]. Serum selenium levels were associated
with higher fasting plasma glucose and HbA1c [22]. An
observational analysis conducted within the Supplemen-
tation with Antioxidant Vitamins and Minerals (SU.VI.
MAX) trial, in which baseline plasma selenium levels
were positively associated with combined fasting plasma
glucose at baseline and after 7.5 years of follow-up [23].
These findings are in contrast with a cross-sectional
analysis of the Health Professionals Study, which showed
an inverse association between toenail selenium and dia-
betes prevalence [24].
It is noteworthy that a study in the early 80s showed
elevated serum selenium levels in diabetic children com-
pared with healthy counterparts [25]. The authors
explained the difference by the altered lipid metabolism
[25]. A study in females with gestational diabetes melli-
tus showed that females with gestational diabetes melli-
tus and those with glucose intolerants had lower serum
selenium levels than that of the normal pregnant
women [26]. The same study found a significant inverse
correlation between serum selenium and blood glucose
levels that is in accordance with our results [26].
A study aiming to evaluate the association between toe-
nail selenium and CAD among men with diabetes showed
that levels of selenium were lower among diabetic men
with or without CAD than among healthy controls [24].
However, this study could not distinguish between the
effects of selenium on diabetes and those on CAD [23]. In
healthy subjects, two studies reported a null association
between selenium and risk of CAD [27,28]. Finally a
recent analysis of the Olivetti Heart Study failed to show
possible associations between selenium levels and cardio-
metabolic risk factors in healthy men [29].
Limitations
The present study has its limitations. First of all no power
sample calculation was performed that could eliminate
possible error type II in the study. In addition, the present
study as a retrospective one can not clarify if selenium acts
as a marker or as a cause of CAD in diabetic subjects.
Also, physical activity, energy intake and presence of meta-
bolic syndrome were not examined for possible associa-
tions with selenium levels in the two study groups. In
addition, other comorbidities correlated with selenium
levels as lung cancer and asthma were not examined.
Finally, the findings of the present study refer to diabetic
population attending an outpatient clinic and, therefore, an
etiology hypothesis cannot be confirmed with this study.
Conclusions
In conclusion, the present study showed that serum
selenium levels did not differ between diabetic subjects
with and without CAD. These results showed that
Table 2 Multivariate linear regression analysis: the
association between various parameters with serum
selenium and in diabetic subjects with and without
coronary artery disease (CAD)
b P
Diabetic subjects with CAD (Model 1)
Gender (males vs. females) 0.21 0.03
Glucose 0.25 0.008
Diabetic subjects without CAD (Model 2)
Peripheral artery disease (yes vs. no) 0.16 0.05
Glucose -0.09 0.06
b: standardized regression coefficient.
Additional variables tested in model 1: body mass index, platelets and C-
reactive protein.
Additional variables tested in model 2: systolic and diastolic blood pressure.
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used for the prevention of CAD in diabetic subjects.
However, further, longitudinal studies are needed in
order to evaluate the role of serum selenium levels in
T2D and CAD.
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